QUALITY ASSURANCE OF VARI-SOURCE HIGH DOSE RATE (HDR) BRACHYTHERAPY- REMOTE AFTER LOADER AND COST EFFECTIVENESS OF VARI-SOURCE HDR- BRACHYTHERAPY: NORI, ISLAMABAD EXPERIENCE

Authors

  • N. Ahmad Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan
  • H. Mahmood Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan
  • S.R. A. Jafri Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan

Abstract

A quality control of Vari-Source high dose rate (HDR) remote after loading brachytherapy machine was carried out and the cost effectiveness of HDR brachytherapy machine was also evaluated considering the cost of ten Iridium-192 wire sources at Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan. A total number of 253 intracavitary insertions were done in 98 patients from October 1996 to May 2001. The results of the quality control tests performed during 1996 to 2001 were within the acceptable limits. The cost effectiveness of Vari-Source HDR brachytherapy machine was also evaluated. The average cost per patient was calculated as US$ 491. Small number of patients was treated as the machine was used for gynecologic malignancies only. The objective was to assess the quality control status of HDR brachytherapy machine on patient treatment day, source exchange day and periodic day (monthly basis). It was found that the cost per patient can be minimized if other type of cancer patients are also treated on Vari-Source HDR machine.

References

ICRU, International Commission on Radiation Units and Measurements, Dose and Volume Specification for Reporting Intracavitary Therapy in Gynaecology, ICRU Report-38 USA, (1985).

Vari Source, System Manual, Issue 1, Varian Oncology Systems, United Kingdom (1996).

WHO, World Health Organization, Quality Assurance in Radiotherapy, Geneva (1988) 32.

B. Erickson and J.F. Wilson, J. Surg. Oncol., 65 No. 3 (1997) 218.

H. Ikeda, Gan To Kagaku Ryoho, 10 (1995) 1317.

N. Sahoo, Med. Phys., 28, No. 8 (2001) 1786.

C.G. Orton, Acta Oncol., 37, No. 2 (1998) 117.

D.G. Petereit, J.N. Sarkaria, D.M. Potter and J.C. Schink, Int. J. Radiat. Oncol. Biol. Phys., 45, No. 5 (1999) 1267.

J.A. Stitt, Hematol Oncol. Clin. North Am., 13, No. 3 (1999) 585.

S. Nag, M. Dally, M. de la Torre, H. Tatsuzaki, N. Kizilbash, S. Kurusun, L. Pinllos, B. Pokrajac, R. Sur and V. Levin, Recommendations for implementation of high dose rate Ir-192 brachytherapy in developing countries by the Advisory Group of International Atomic Energy Agency, 64, No. 3 (2002) 297.

S. Nag, Clinical aspect of high dose rate brachytherapy, Principle and practice of radiation oncology, Philadelphia, Lippincott (2004) 619-635.

M. Humera, Role of HDR brachytherapy in gynaecological malignancies -experience at NORI, 10th Annual conference of Pakistan Society of Clinical Oncology, (2003) Peshawar, Pakistan.

T. Inou, Gan To Kagaku Ryoho., 25, No. 1 (1998) 13.

J. Pinilla, Int. J. Radiat. Oncol. Biol. Phys., 42, No. 1 (1998) 87.

Downloads

Published

09-07-2020

How to Cite

[1]
N. Ahmad, H. Mahmood, and S. A. Jafri, “QUALITY ASSURANCE OF VARI-SOURCE HIGH DOSE RATE (HDR) BRACHYTHERAPY- REMOTE AFTER LOADER AND COST EFFECTIVENESS OF VARI-SOURCE HDR- BRACHYTHERAPY: NORI, ISLAMABAD EXPERIENCE”, The Nucleus, vol. 41, no. 1-4, pp. 35–40, Jul. 2020.

Issue

Section

Articles

Most read articles by the same author(s)

<< < 1 2